Fingerprint
Dive into the research topics of 'Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically